Antibiotic Susceptibility Patterns of Gut Microbiota in Inflammatory Bowel Disease
Keywords:
Inflammatory bowel disease (IBD), Ulcerative colitis(UC), Crohn’s disease(CD), antibiotics, age-standardised mortality rate(ASMR), age-standardised prevalence rate(ASPR), endoscopy, ileoscopyAbstract
Inflammatory bowel disease (IBD) involves inflammation of the digestive tract and intestines. This inflammation leads to the development of ulcers and causes discomfort during bowel movements. The primary contributors to IBD are poor dietary habits and a lack of physical activity. Inflammation occurs from mouth to anus because of toxic substances released by the bacteria into the system. This study focuses on the antibiotic resistance and susceptibility of the microorganisms that cause IBD. The methodology is based on earlier research related to ASMR and ASPR. Utilizing data till 2019, predictions of IBD incidence for the future in India are provided. The results of the antibiotic sensitivity disc test for the positive samples in the study indicate resistance and susceptibility to specific microorganisms linked to IBD. Statistical analysis shows that India accounts for 8% of global IBD cases annually. More than 37,000 cases have been reported in India. Various regions in newly industrialized countries face an increased risk of developing IBD. Reports from 2019 indicate that males are more frequently affected than females. The prevalence of the disease is higher than the mortality rate among patients, which stands at 20.34%. From this study, in 2025 the males are more affected than females, which stands at 41.25%..
Downloads
Metrics
References
Sartor, R.B. and Mazmanian, S.K., 2012. Intestinal microbes in inflammatory bowel diseases. The American journal of gastroenterology supplements, 1(1), p.15.
Toychiev, A., Navruzov, B., Pazylova, D., Davis, N., Badalova, N. and Osipova, S., 2021. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Acta Tropica, 213, p.105755.
Dolan, K.T. and Chang, E.B., 2017. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Molecular nutrition & food research, 61(1), p.1600129.
Kirsner, J.B. and Shorter, R.G., 1982. Recent developments in nonspecific inflammatory bowel disease. New England Journal of Medicine, 306(13), pp.775-785.
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K. and Kunisaki, R., 2018. Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of gastroenterology, 53(3), pp.305-353.
Singh, S., Blanchard, A., Walker, J.R., Graff, L.A., Miller, N. and Bernstein, C.N., 2011. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology, 9(9), pp.769-775.
Shergill, A.K., Lightdale, J.R., Bruining, D.H., Acosta, R.D., Chandrasekhara, V., Chathadi, K.V., Decker, G.A., Early, D.S., Evans, J.A., Fanelli, R.D. and Fisher, D.A., 2015. The role of endoscopy in inflammatory bowel disease. Gastrointestinal endoscopy, 81(5), pp.1101-1121.
Kaplan, G.G. and Ng, S.C., 2017. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology, 152(2), pp.313-321.
Click, B., Barnes, E.L., Cohen, B.L., Sands, B.E., Hanson, J.S., Regueiro, M., Rubin, D.T., Dubinsky, M.C., Gazis, D.R., Dalfonso, L. and Hildebrand, J.S., 2021. Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD. Crohn's & Colitis 360, 3(3), p.otab023.
Nikolaus, S. and Schreiber, S., 2007. Diagnostics of inflammatory bowel disease. Gastroenterology, 133(5), pp.1670-1689.
Nitzan, O., Elias, M., Peretz, A. and Saliba, W., 2016. Role of antibiotics for the treatment of inflammatory bowel disease. World journal of gastroenterology, 22(3), p.1078.
Laranjeira, N., Fonseca, J., Meira, T., Freitas, J., Valido, S. and Leitão, J., 2015. Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients. Arquivos de gastroenterologia, 52, pp.105-110.
Zhang, M., Sun, K., Wu, Y., Yang, Y., Tso, P. and Wu, Z., 2017. Interactions between intestinal microbiota and host immune response in inflammatory bowel disease. Frontiers in immunology, 8, p.942.
Xu, M., Zhang, W., Lin, B., Lei, Y., Zhang, Y., Zhang, Y., Chen, B., Mao, Q., Kim, J.J. and Cao, Q., 2025. Efficacy of probiotic supplementation and impact on fecal microbiota in patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 83(2), pp.e65-e73.
Forss, A., 2022. Medical and surgical treatment of inflammatory bowel disease. Karolinska Institutet (Sweden).
Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R., Ghosh, S., Wu, J.C., Chan, F.K. and Sung, J.J., 2017. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet, 390(10114), pp.2769-2778.
Wehkamp, J., Götz, M., Herrlinger, K., Steurer, W. and Stange, E.F., 2016. Inflammatory bowel disease: Crohn’s disease and ulcerative colitis. Deutsches Ärzteblatt International, 113(5), p.72.
Marks, D.J., Miyagi, K., Rahman, F.Z., Novelli, M., Bloom, S.L. and Segal, A.W., 2009. Inflammatory bowel disease in CGD reproduces the clinical and pathological features of Crohn's disease. Official journal of the American College of Gastroenterology| ACG, 104(1), pp.117-124.
Seyedian, S.S., Nokhostin, F. and Malamir, M.D., 2019. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life, 12(2), p.113.
Sharma, V., 2025. Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019..
.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
